Shots:

• Takeda to receive $505M cash at closing- $70M in non-contingent cash to be paid within 4yrs. post-closing- $95M as milestones. Takeda will divest ~110 select OTC and prescription pharmaceutical assets sold in the EU
• The transaction is expected to be closed by the end of 2020. The divestiture will allow Takeda to prioritize and reinforce efforts in its core business areas
• Two manufacturing sites in Denmark and Poland along with ~600 employees will be transferred to Orifarm. Additionally- the companies have signed a manufacturing and supply agreements- under which Takeda will continue to manufacture selected products while Orifarm will acquire the rights- title- and interest to the products in the portfolio exclusive to these countries

Click here ­to­ read full press release/ article | Ref: Takeda | Image: Takeda

Related News:  Takeda to Divest a Portfolio of Select OTC and Non-Core Assets to Hypera Pharma in Latin America for $825M